Advanced Filters
noise

Rosklide, Denmark Clinical Trials

A listing of Rosklide, Denmark clinical trials actively recruiting patients volunteers.

Found 65 clinical trials
L Laura K Hakala

Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL).

18 - 64 years of age Both Phase 2

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

18 - 100 years of age Both Phase 3
B Bo Madsen, Consultant

Prophylactic Antibiotic Treatment in Hemodialysis

The purpose of this study is to assess the efficacy of prophylactic antibiotic treatment on blood stream infections and severe culture negative infections, in patients on newly started hemodialysis(HD), with a central venous catheter as vascular access.

18 - 100 years of age Both Phase N/A

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

18 - 99 years of age Both Phase 3
C Christoph Beier, M.D.

Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)

This open-label, randomized multicenter trial aims at clarifying the standard of care of patients with non-convulsive status epilepticus not responding to treatment with benzodiazepines and at least one high-dose intra venous anti-seizure medication.

18 - 120 years of age Both Phase 3
N Nessn H. Azawi, M.D.

Personalized Treatment of Urogenital Cancers Depends on the Microbiome

This is a randomized controlled trial where patients undergoing surgical treatment for urogenital cancers will be randomized in a two arms study: surgical treatment + antibiotics OR surgical treatment + placebo.

40 - 70 years of age Both Phase N/A

NORTH-REG Dwell-Time Study

Previous studies show that the majority NMIBC patients experience side effects to BCG and therefore terminate the instillations before completing all planned instillations. This will increase their risk of recurrence and potential cystectomy. The purpose of this study is to investigate if NMIBC patients who experience severe side effects to …

18 - 100 years of age Both Phase 4

En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer

Aim: To compare the surgical method of En Bloc resection to the conventional transurethral resection of non-muscle invasive bladder cancer (NMIBC) in terms of complete removal of tumour, specimen quality, and pathological certainty. Background: NMIBC is a common disease with a 5-year recurrence rate reported as high as 64%. The …

18 - 100 years of age Both Phase N/A
U Ulla B Henningsen

eHealth Intervention to Manage Depression and Anxiety in Patients With Ischemic Heart Disease

This study evaluates the effectiveness and cost-effectiveness of a therapy-assisted internet-based intervention in patients with ischemic heart disease and co-morbid depression and anxiety referred for cardiac rehabilitation. Half of the patients will receive the intervention and the other half usual care. We hypothesize that the intervention will lead to a …

18 - 100 years of age Both Phase N/A
C Cæcilie Borregaard Myrhøj

Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

Patients diagnosed with hematologic cancer are at substantial risk of dying, as 5-year survival among patients with acute myeloid leukemia is 20 % and only every second patient treated for incurable myeloma lives 5 years after date of diagnosis. Nevertheless, many overestimate their prognosis, and value of therapy. Patients with …

18 - 100 years of age Both Phase N/A

Rewrite in simple language using AI